Portfolio Holdings Detail for ISIN IE00BMXC7V63

Stock Name / Fund	iShares S&P 500 Paris-Aligned Climate UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	UPABz(USD) CXE
ETF Ticker	UQAB.DE(EUR) CXE
ETF Ticker	UPAB(USD) Euronext Amsterdam

Holdings detail for MRK

Show aggregate MRK holdings

News associated with MRK

Surprising Analyst 12-Month Target For FDL

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-22 08:04:45

IWD, JNJ, MCD, MRK: Large Inflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $565.9 million dollar inflow -- that's a 0.9% increase week over w - 2025-09-18 13:26:06

Daiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation

(RTTNews) - Daiichi Sankyo Company Limited (DSKYF) and Merck & Co Inc. (MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for their raludotatug deruxtecan for the treatment of adults with platinum-resistant epithelia - 2025-09-15 08:43:59

Peter Lynch Detailed Fundamental Analysis - MRK

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-12 10:32:51

Guru Fundamental Report for MRK - Peter Lynch

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-11 10:33:21

Notable ETF Inflow Detected - VYM, JNJ, MRK, CME

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $440.7 million dollar inflow -- that's a 0.7% increase week over - 2025-09-10 11:50:46

MRK Factor-Based Stock Analysis - Peter Lynch

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-10 10:34:14

Daiichi Sankyo And Merck : Ifinatamab Deruxtecan Shows Promising Results In Phase 2 ES-SCLC Trial

(RTTNews) - Daiichi Sankyo (DSKYF, 4568.T) and Merck & Co Inc. (MRK) announced that Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small c - 2025-09-08 02:18:22

Peter Lynch Detailed Fundamental Analysis - MRK

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-05 10:33:56

Pre-Market Most Active for Sep 5, 2025 : OPEN, TSLL, SCAG, SQQQ, MRK, NVDA, KO, AVGO, SNAP, FIG, WMT, NIO

The NASDAQ 100 Pre-Market Indicator is up 147.96 to 23,780.97. The total Pre-Market volume is currently 100,628,631 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is +0.27 at $6.23, with 12,819,663 shares trade - 2025-09-05 09:29:53

Guru Fundamental Report for MRK - Peter Lynch

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-04 10:32:25

MRK Factor-Based Stock Analysis - Peter Lynch

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-03 10:34:47

Peter Lynch Detailed Fundamental Analysis - MRK

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-29 10:33:23

MRK's Strong Dividend History Helps it Reach 'Top Dividend Stock of the Dow'

Merck & Co Inc (Symbol: MRK) has been named as the ''Top Dividend Stock of the Dow'', according to Dividend Channel, which published its most recent ''DividendRank'' report. The report noted that among the components of the Dow Jones Industrial Average, MRK shares displayed b - 2025-08-28 08:50:04

MRK Factor-Based Stock Analysis - Peter Lynch

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-27 10:34:49

MRK Quantitative Stock Analysis - Peter Lynch

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-26 10:34:02

iShares MSCI ACWI ETF Experiences Big Outflow

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ETF (Symbol: ACWI) where we have detected an approximate $429.5 million dollar outflow -- that's a 1.9% decrease week over week (f - 2025-08-25 13:36:45

Peter Lynch Detailed Fundamental Analysis - MRK

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-22 10:34:21

Dow Movers: WMT, MRK

In early trading on Thursday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.2%. Year to date, Merck has lost about 13.8% of its value. And the worst performing Dow component thus far on the day is Walmart, tr - 2025-08-21 11:27:42

MRK Factor-Based Stock Analysis - Peter Lynch

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-20 10:34:00

After Hours Most Active for Aug 19, 2025 : CSX, INTC, MRK, NVDA, IBN, KO, FUN, PEP, CX, WMT, HTZ, QQQ

The NASDAQ 100 After Hours Indicator is down -1.71 to 23,383.06. The total After hours volume is currently 259,932,235 shares traded.The following are the most active stocks for the after hours session: CSX Corporation (CSX) is -0.04 at $36.48, with 11,794,785 shares traded. Ove - 2025-08-19 17:24:59

Daiichi Sankyo Announces Breakthrough Therapy Designation For Ifinatamab Deruxtecan

(RTTNews) - Daiichi Sankyo announced that Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. The FDA g - 2025-08-18 08:36:51

The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey

Analysts spotlight Merck, Palo Alto Networks, Freeport-McMoRan, and Espey as innovation, contract wins, and industry trends shape growth prospects. - 2025-08-15 12:44:00

Noteworthy ETF Outflows: SUSL, MCD, DIS, MRK

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares ESG MSCI USA Leaders ETF (Symbol: SUSL) where we have detected an approximate $84.6 million dollar outflow -- that's a 8.7% decrease week ov - 2025-08-15 11:49:25

Peter Lynch Detailed Fundamental Analysis - MRK

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-15 10:31:59

Top Analyst Reports for Merck, Palo Alto & Freeport

Merck leans on Keytruda growth and pipeline expansion, Palo Alto rides subscription security demand, and Freeport benefits from electrification-driven copper demand. - 2025-08-14 17:46:00

Stocks See Support As Bessent Calls for a Big Rate Cut

The S&P 500 Index ($SPX ) (SPY ) on Wednesday rose +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) rose +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +0.04%. September E-mini S&P futures (ESU25 ) rose +0.32%, and September E-mini Nasdaq futures (NQU25 ) fell... - 2025-08-14 15:15:33

MRK April 2026 Options Begin Trading

Investors in Merck & Co Inc (Symbol: MRK) saw new options become available today, for the April 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 246 days until expiration the newly available contra - 2025-08-14 14:30:24

Stocks See Support As Bessent Calls for a Big Rate Cut

The S&P 500 Index ($SPX ) (SPY ) on Wednesday rose +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) rose +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +0.04%. September E-mini S&P futures (ESU25 ) rose +0.32%, and September E-mini Nasdaq futures (NQU25 ) fell... - 2025-08-14 14:05:26

Stocks See Support As Bessent Calls for a Big Rate Cut

The S&P 500 Index ($SPX ) (SPY ) on Wednesday rose +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) rose +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +0.04%. September E-mini S&P futures (ESU25 ) rose +0.32%, and September E-mini Nasdaq futures (NQU25 ) fell... - 2025-08-14 12:17:47

iShares S&P 500 Paris-Aligned Climate UCITS ETF USD (Acc) MRK holdings

Date	Number of MRK Shares Held	Base Market Value of MRK Shares	Local Market Value of MRK Shares	Change in MRK Shares Held	Change in MRK Base Value	Current Price per MRK Share Held	Previous Price per MRK Share Held
2025-12-02 (Tuesday)	45,110	USD 4,557,463	USD 4,557,463	-1,014	USD -139,344	USD 101.03	USD 101.83
2025-12-01 (Monday)	46,124	USD 4,696,807	USD 4,696,807	0	USD -138,372	USD 101.83	USD 104.83
2025-11-28 (Friday)	46,124	USD 4,835,179	USD 4,835,179	-338	USD -73,996	USD 104.83	USD 105.66
2025-11-25 (Tuesday)	46,462	USD 4,909,175	USD 4,909,175	338	USD 278,325	USD 105.66	USD 100.4
2025-11-24 (Monday)	46,124	USD 4,630,850	USD 4,630,850	0	USD 121,768	USD 100.4	USD 97.76
2025-11-21 (Friday)	46,124	USD 4,509,082	USD 4,509,082	0	USD 128,686	USD 97.76	USD 94.97
2025-11-20 (Thursday)	46,124	USD 4,380,396	USD 4,380,396	-169	USD -83,638	USD 94.97	USD 96.43
2025-11-18 (Tuesday)	46,293	USD 4,464,034	USD 4,464,034	0	USD 165,266	USD 96.43	USD 92.86
2025-11-17 (Monday)	46,293	USD 4,298,768	USD 4,298,768	-1,352	USD -128,405	USD 92.86	USD 92.92

Share Trades of MRK by Blackrock for IE00BMXC7V63

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	SELL	-1,014	101.800	100.310	100.459	GBX -101,865	87.87 Loss of -12,766 on sale
2025-11-28	SELL	-338	105.405	104.120	104.249	GBX -35,236	87.72 Loss of -5,586 on sale
2025-11-25	BUY	338	105.840	100.705	101.219	GBX 34,212	87.64
2025-11-20	SELL	-169	96.000	93.900	94.110	GBX -15,905	87.49 Loss of -1,119 on sale
2025-11-17	SELL	-1,352	94.740	92.675	92.882	GBX -125,576	87.42 Loss of -7,385 on sale
2025-11-03	SELL	-4,200	86.100	82.340	82.716	GBX -347,407	87.43 Profit of 19,795 on sale
2025-10-31	BUY	168	86.460	84.560	84.750	GBX 14,238	87.44
2025-10-23	SELL	-672	88.105	86.910	87.030	GBX -58,484	87.45 Profit of 281 on sale
2025-10-22	SELL	-336	88.790	87.030	87.206	GBX -29,301	87.45 Profit of 81 on sale
2025-10-01	SELL	-169	90.750	85.190	85.746	GBX -14,491	87.49 Profit of 295 on sale
2025-09-29	SELL	-2,873	78.800	78.030	78.107	GBX -224,401	87.57 Profit of 27,175 on sale
2025-09-18	BUY	155			81.530*		87.71
2025-08-20	BUY	775			84.660*		87.82
2025-08-15	SELL	-310	84.740	83.360	83.498	GBX -25,884	87.88 Profit of 1,358 on sale
2025-07-15	SELL	-1,085	84.360	81.300	81.606	GBX -88,543	88.23 Profit of 7,187 on sale
2025-07-11	SELL	-1,395	84.130	82.260	82.447	GBX -115,014	88.29 Profit of 8,154 on sale
2025-07-09	SELL	-310	84.480	81.890	82.149	GBX -25,466	88.35 Profit of 1,923 on sale
2025-07-03	SELL	-310	82.600	80.700	80.890	GBX -25,076	88.55 Profit of 2,375 on sale
2025-07-02	SELL	-1,550	82.790	81.894	81.983	GBX -127,074	88.59 Profit of 10,247 on sale
2025-06-30	SELL	-4,495	79.390	78.380	78.481	GBX -352,772	88.66 Profit of 45,752 on sale
2025-06-20	BUY	18,377	79.920	78.600	78.732	GBX 1,446,858	89.06
2025-06-13	SELL	-864	82.440	81.450	81.549	GBX -70,458	89.40 Profit of 6,784 on sale
2025-06-12	SELL	-648	82.110	80.070	80.274	GBX -52,018	89.46 Profit of 5,951 on sale
2025-06-11	SELL	-1,962	81.680	79.980	80.150	GBX -157,254	89.53 Profit of 18,399 on sale
2025-06-10	SELL	-2,376	81.880	79.330	79.585	GBX -189,094	89.59 Profit of 23,774 on sale
2025-06-05	BUY	648	78.550	77.250	77.380	GBX 50,142	89.85
2025-05-19	SELL	-108			77.230*		91.29 Profit of 9,859 on sale
2025-05-13	BUY	324			76.630*		91.87
2025-05-02	BUY	424	84.710	82.950	83.126	GBX 35,245	92.70
2025-05-01	SELL	-540	84.575	83.170	83.310	GBX -44,988	92.79 Profit of 5,119 on sale
2025-04-28	SELL	-1,836	83.680	82.400	82.528	GBX -151,521	93.05 Profit of 19,310 on sale
2025-04-16	BUY	432	78.690	75.930	76.206	GBX 32,921	94.30
2025-04-08	BUY	648	83.270	77.540	78.113	GBX 50,617	95.36
2025-04-07	SELL	-1,728	83.210	79.300	79.691	GBX -137,706	95.53 Profit of 27,371 on sale
2025-04-04	SELL	-324	86.260	81.090	81.607	GBX -26,441	95.70 Profit of 4,566 on sale
2025-03-28	SELL	-5,450			89.230*		96.08 Profit of 523,640 on sale
2025-03-27	SELL	-218			87.600*		96.19 Profit of 20,969 on sale
2025-03-24	SELL	-218			92.310*		96.46 Profit of 21,028 on sale
2025-03-21	SELL	-6,674			93.110*		96.51 Profit of 644,075 on sale
2025-03-18	SELL	-2,904			94.720*		96.59 Profit of 280,498 on sale
2025-03-14	SELL	-825			94.570*		96.65 Profit of 79,733 on sale
2025-03-13	SELL	-121			94.710*		96.67 Profit of 11,698 on sale
2025-03-12	BUY	1,210			93.350*		96.72
2025-03-11	BUY	1,573			94.730*		96.75
2025-03-07	BUY	726			94.650*		96.81
2025-03-05	BUY	1,573			93.190*		96.87
2025-02-26	BUY	242	91.370	88.860	89.111	GBX 21,565	97.32
2025-02-12	BUY	242	86.670	85.610	85.716	GBX 20,743	99.58
2025-02-05	BUY	484	90.740	87.995	88.270	GBX 42,722	100.98
2025-01-02	BUY	2,420	100.350	98.840	98.991	GBX 239,558	102.08
2024-12-09	SELL	-121	105.070	102.330	102.604	GBX -12,415	102.06 Loss of -66 on sale
2024-12-03	SELL	-242	102.450	100.620	100.803	GBX -24,394	102.00 Profit of 289 on sale
2024-12-02	BUY	121	101.850	100.460	100.599	GBX 12,172	102.05
2024-11-29	BUY	242	103.040	101.530	101.681	GBX 24,607	102.07
2024-11-27	BUY	605	103.450	101.640	101.821	GBX 61,602	101.98
2024-11-26	BUY	726	101.800	99.700	99.910	GBX 72,535	101.99
2024-11-22	BUY	242	101.790	98.930	99.216	GBX 24,010	102.18
2024-11-19	BUY	242	97.550	95.260	95.489	GBX 23,108	102.92
2024-11-18	BUY	363	97.290	95.420	95.607	GBX 34,705	103.32
2024-11-12	BUY	121	100.760	98.500	98.726	GBX 11,946	103.64
2024-11-05	BUY	1,210	101.730	100.520	100.641	GBX 121,776	104.37
2024-10-31	BUY	484	103.230	98.600	99.063	GBX 47,946	105.25
2024-10-30	BUY	1,815	105.000	102.900	103.110	GBX 187,145	105.31
2024-10-21	BUY	242	109.170	106.180	106.479	GBX 25,768	0.00

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MRK

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy